Ruxolitinib for Emergency Treatment of COVID‐19–Associated Cytokine Storm: Findings From an Expanded Access Study
The Clinical Respiratory Journal · 2025
DOI: 10.1111/crj.70050 ↗Kurz gefasst
Klinische Studie in der Zeitschrift The Clinical Respiratory Journal, 2025. Verfasst von Jeffrey Weinstein und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Quality and Infection Prevention and Control, Kettering Health Network, Dayton, Ohio, USA. Hauptthemen laut MEDLINE: Pyrazoles, Cytokine Release Syndrome, COVID-19 Drug Treatment. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Incyte Corporation.
Abstract (Originalsprache)
Introduction
This expanded access program (EAP) provided ruxolitinib (oral, selective Janus kinase [JAK]1/JAK2 inhibitor) for emergency treatment of COVID‐19–associated cytokine storm in patients eligible for hospitalization (NCT04355793).
Methods
Patients received ruxolitinib 5 mg twice daily (preferred regimen when tolerated) or once daily for ≤ 14 days, or until determination of no clinical benefit was made. Outcomes were clinical status, physician‐assessed clinical benefit, and serious adverse event (SAE) incidence.
Results
Of 312 patients, 45.5% achieved ≥ 1‐point clinical status improvement. Physician‐assessed clinical benefit was reported in 42.6% of evaluable patients. SAEs occurred in 42.9%, with 2.6% experiencing an SAE suspected to be ruxolitinib related.
Conclusions
Overall, some hospitalized patients with COVID‐19–associated cytokine storm who received ruxolitinib experienced clinical status improvement; ruxolitinib was well tolerated. Trial Registration ClinicalTrials.gov identifier: NCT04355793
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Quality and Infection Prevention and Control, Kettering Health Network, Dayton, Ohio, USA.
- Department of Medicine, Creighton University School of Medicine, Omaha, Nebraska, USA.
- Medical Affairs, Incyte Corporation, Wilmington, Delaware, USA.
ORCID-Profile: Jeffrey Weinstein
Förderung
- Incyte Corporation
Zitieren
APA
Weinstein, J., Jagan, N., Lorthridge-Jackson, S., Hamer-Maansson, J. E., & Squier, P. (2025). Ruxolitinib for Emergency Treatment of COVID‐19–Associated Cytokine Storm: Findings From an Expanded Access Study. The Clinical Respiratory Journal. https://doi.org/10.1111/crj.70050
Vancouver
Weinstein J, Jagan N, Lorthridge-Jackson S, Hamer-Maansson JE, Squier P. Ruxolitinib for Emergency Treatment of COVID‐19–Associated Cytokine Storm: Findings From an Expanded Access Study. The Clinical Respiratory Journal. 2025. doi:10.1111/crj.70050
BibTeX
@article{Weinstein2025,
author = {Weinstein, Jeffrey and Jagan, Nikhil and Lorthridge-Jackson, Shawnta and Hamer-Maansson, J E and Squier, Peg},
title = {Ruxolitinib for Emergency Treatment of COVID‐19–Associated Cytokine Storm: Findings From an Expanded Access Study},
journal = {The Clinical Respiratory Journal},
year = {2025},
doi = {10.1111/crj.70050}
}
EUVIMED